|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
These findings suggest that miR-592 acted as a tumor suppressor by targeting ROCK1 and may serve as a potential biomarker in AML.
|
30840284 |
2019 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The results indicated that miR‑592 was significantly downregulated in thyroid cancer samples, and its downregulation was associated with lymph node metastasis and tumor‑node‑metastasis stage.
|
31524231 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
These findings suggested that miR-592 functions as tumor suppressor in NSCLC by suppressing the activity of SOX9, and that miR-592 might serve as a promising therapeutic target for NSCLC treatment.
|
28004116 |
2017 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The statistical analysis revealed that low expression of miR-592 was evidently associated with tumor node metastasis stage and lymph node metastasis.
|
28529580 |
2017 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Moreover, the in vivo study showed that microRNA-592 overexpression produced the smaller tumor volume and weight in nude mice.
|
28718372 |
2017 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Our clinicopathological analysis revealed that high miR-592 was significant associated with the tumor size (P=0.008), TNM stage (P=0.026), distant metastasis (P=0.004) and preoperative CEA level (P=0.022), which led to a shorter overall survival rate in CRC patients (P=0.032).
|
25661360 |
2015 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Few associations were found between clinical parameters and miRNA expression, among them, low expression of miR-592 and high expression of miR-10b-5p and miR-615-3p were associated with tumors located in the right colon relative to the left colon and rectum.
|
23824282 |
2013 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Significant differences were also seen in 6 miRNAs including miR-31 and miR-592, in the direct comparison of tumors that were deficient or proficient for mismatch repair.
|
19922656 |
2009 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Finally, ROCK1 overexpression rescued the effect of miR-592-mediated AML cell proliferation and metastasis.
|
30840284 |
2019 |
|
Neoplasm Metastasis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
The results indicated that miR‑592 was significantly downregulated in thyroid cancer samples, and its downregulation was associated with lymph node metastasis and tumor‑node‑metastasis stage.
|
31524231 |
2019 |
|
Neoplasm Metastasis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
The statistical analysis revealed that low expression of miR-592 was evidently associated with tumor node metastasis stage and lymph node metastasis.
|
28529580 |
2017 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Statistical analysis revealed that decreased miR-592 was negatively associated with advanced clinical stage, distant metastasis and lymph node metastases.
|
29039599 |
2017 |
|
Neoplasm Metastasis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that miR-592 may promote the progression and metastasis, in part, by targeting FoxO3A in CRC. miR-592 may be a novel target for CRC treatment and antagomir-592 may inhibit the proliferation and metastasis of CRC cells.
|
27167185 |
2016 |